RESUMEN
Objetivo. Establecer la utilidad de las concentraciones de neuroquinina B como marcador de riesgo en pacientes con preeclampsia. Método. Se seleccionó a un total de 100 pacientes. Se incluyeron a 50 pacientes con preeclampsia como los casos (grupo A) y un grupo control seleccionado por tener una edad y un índice de masa corporal similares al grupo de estudio, que consistió en 50 gestantes normotensas sanas (grupo B). Las muestras de sangre se recolectaron en todas las pacientes antes del parto e inmediatamente después del diagnóstico en el grupo B para determinar las concentraciones de neuroquinina B. Resultados. Se encontraron diferencias estadísticamente significativas en las concentraciones de neuroquinina B entre las pacientes en el grupo de estudio (grupo A; 16,3±9,6ng/l) y las pacientes del grupo control (grupo B; 3,5±2,0ng/l; p<0,05). Se observó una correlación positiva y significativa con los valores de presión arterial sistólica y diastólica (p<0,05). Un valor de corte de 5pg/ml presentó un valor por debajo de la curva de 0,93 y tiene una sensibilidad del 75,0%, una especificidad del 87,5%, un valor predictivo positivo del 90,0% y un valor predictivo negativo del 70,0% con una exactitud diagnóstica de 81,2%. Conclusiones. Las pacientes con preeclampsia presentaron concentraciones significativamente más altas de neuroquinina B al compararlas con gestantes normotensas sanas. Este péptido es útil como marcador de riesgo en pacientes con preeclampsia (AU)
Objective. To establish the usefulness of neurokinin B concentrations as a risk marker in patients with preeclampsia. Method. A total of 100 patients were selected. Fifty patients with preeclampsia were selected as cases (group A) and 50 healthy normotensive pregnant women with a similar age and body mass index to the study group were selected as controls (group B). Blood samples were collected in all patients before labor and immediately after diagnosis in group B to determine neurokinin B concentrations. Results. Statistically significant differences in neurokinin B concentrations were found between group A (16.3±9.6ng/L) and group B (3.5±2.0ng/L; P<.05). There was a positive and significant correlation with values of systolic and diastolic blood pressure (P<.05). A cut-off value of 5pg/ml had a value under the curve of 0.93, sensitivity of 75.0%, specificity of 87.5%, a positive predictive value of 90.0%, a negative predictive value of 70.0%, and a diagnostic accuracy of 81.2%. Conclusions. Concentrations of neurokinin B were significantly higher in patients with preeclampsia than in healthy normotensive pregnant women. This peptide is useful as a risk marker in patients with preeclampsia (AU)
Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Preeclampsia/diagnóstico , Preeclampsia/tratamiento farmacológico , Neuroquinina B , Complicaciones del Embarazo/diagnóstico , Sensibilidad y Especificidad , Neuroquinina B/síntesis química , Índice de Masa Corporal , Factores de Riesgo , Embarazo de Alto Riesgo/metabolismoRESUMEN
AIM: To develop nonpeptide tachykinin NK3 antagonists. METHODS: Five tachykinin NK3 antagonists were synthesized. Receptor binding assay and oral absorption study were made. RESULTS: The 4,4-disubstituted piperidine compounds (1b, 1c, and 1d) showed stronger activities (IC50 = 5.9, 6.2, and 11 nmol.L-1, respectively) than the monosubstituted ring compound 1e (IC50 = 17 nmol.L-1). 4-Phenyl (1b) and 4-phenylsulfonylmethyl (1c) compounds were more active than the 4-fluorobenzyl compound (1d). All antagonists were found to be orally absorbable, the T1/2 of 1b (6.4 h) was more than three-fold longer than that of 1a (1.9 h). CONCLUSION: Compound 1b had the best binding activity (IC50 = 5.9 nmol.L-1) and the best AUC (2081 micrograms.h.L-1).